Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-7b9c58cd5d-wdhn8 Total loading time: 0 Render date: 2025-03-14T19:53:21.533Z Has data issue: false hasContentIssue false

7.2 - Systemic therapies for advanced hepatocellular carcinoma

from 7 - Non-surgical treatment of hepatocellular carcinoma

Published online by Cambridge University Press:  04 August 2010

By
Orit Gutfeld ,
Charlie Pan ,
Edward Kim  and
Mark M. Zalupski
Edited by
Hero K. Hussain  and
Isaac R. Francis
Hero K. Hussain
Affiliation:
University of Michigan Medical School, Ann Arbor
Isaac R. Francis
Affiliation:
University of Michigan Medical School, Ann Arbor
Get access

Summary

Introduction

Historically, radiotherapy (RT) had an extremely limited role in the treatment of liver malignancies due to the low tolerance of the whole liver to radiation. The risk of radiation-induced liver disease (RILD) limits the dose that can be safely delivered to the whole liver to only 30–35 Gy in 2-Gy fractions, a dose that is well below the doses needed to eradicate solid tumors. The development of three-dimensional conformal RT (3-D CRT) allows the delivery of higher radiation doses to the tumor while minimizing the dose to the surrounding uninvolved liver. Advances in tumor targeting via improved diagnostic imaging, techniques to control or account for motion of the liver due to respiration, and the use of image guidance enable us to further escalate the dose to the tumor without increasing the toxicity.

Studies using modern RT techniques and higher doses for treating hepatocellular carcinoma (HCC) have shown encouraging results. The concepts of liver RT, the techniques, and the available clinical data will be reviewed in this chapter.

Liver tolerance to radiation

RILD may develop between 2 weeks to 4 months after hepatic irradiation and is characterized by anicteric hepatomegaly, ascites, and impaired liver function tests, occurring in the absence of disease progression. Serum alkaline phosphatase is typically markedly elevated, with only moderate elevations of liver transaminases and little or no increase in bilirubin.

Type
Chapter
Information
Primary Carcinomas of the Liver , pp. 97 - 121
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lawrence, TS, Robertson, JM, Anscher, MS, Jirtle, RL, Ensminger, WD, and Fajardo, LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31(5): 1237–48.CrossRefGoogle ScholarPubMed
Lyman, JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985; 8: S13–19.CrossRefGoogle ScholarPubMed
McGinn, CJ, Ten Haken, RK, Ensminger, WD, Walker, S, Wang, S, and Lawrence, TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998; 16(6): 2246–52.CrossRefGoogle ScholarPubMed
Dawson, , McGinn, CJ, Normolle, D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18(11): 2210–18.CrossRefGoogle ScholarPubMed
Ben-Josef, E, Normolle, D, Ensminger, WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23(34): 8739–47.CrossRefGoogle ScholarPubMed
Dawson, , Normolle, D, Balter, JM, McGinn, CJ, Lawrence, TS, and Ten Haken, RKAnalysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53(4): 810–21.CrossRefGoogle ScholarPubMed
Cheng, JC, Wu, JK, Lee, PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004; 60(5): 1502–9.CrossRefGoogle ScholarPubMed
Xu, ZY, Liang, SX, Zhu, J, et al. Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. Int J Radiat Oncol Biol Phys 2006; 65(1): 189–95.CrossRefGoogle ScholarPubMed
Liang, SX, Zhu, XD, Xu, ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006; 65(2): 426–34.CrossRefGoogle ScholarPubMed
Yamasaki, SA, Marn, CS, Francis, IR, Robertson, JM, and Lawrence, TS. High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis. AJR Am J Roentgenol 1995; 165(1): 79–84.CrossRefGoogle ScholarPubMed
Herfarth, KK, Hof, H, Bahner, ML, et al. Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 2003; 57(2): 444–51.CrossRefGoogle ScholarPubMed
Chiou, SY, Lee, RC, Chi, KH, Chia-Hsien, Cheng J, Chiang, JH, and Chang, CY. The triple-phase CT image appearance of post-irradiated livers. Acta Radiol 2001; 42(5): 526–31.CrossRefGoogle ScholarPubMed
Ahmadi, T, Itai, Y, Onaya, H, Yoshioka, H, Okumura, T, and Akine, Y. CT evaluation of hepatic injury following proton beam irradiation: Appearance, enhancement, and 3D size reduction pattern. J Comput Assist Tomogr 1999; 23(5): 655–63.CrossRefGoogle ScholarPubMed
Onaya, H, Itai, Y, Yoshioka, H, et al. Changes in the liver parenchyma after proton beam radiotherapy: Evaluation with MR imaging. Magn Reson Imaging 2000; 18(6): 707–14.CrossRefGoogle ScholarPubMed
Onaya, H, Itai, Y, Ahmadi, T, et al. Recurrent hepatocellular carcinoma versus radiation-induced hepatic injury: Differential diagnosis with MR imaging. Magn Reson Imaging 2001; 19(1): 41–6.CrossRefGoogle ScholarPubMed
Voroney, JP, Brock, KK, Eccles, C, Haider, M, and Dawson, . Prospective comparison of computed tomography and magnetic resonance imaging for liver cancer delineation using deformable image registration. Int J Radiat Oncol Biol Phys 2006; 66(3): 780–91.CrossRefGoogle ScholarPubMed
Eccles, C, Brock, KK, Bissonnette, JP, Hawkins, M, and Dawson, . Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys 2006; 64(3): 751–9.CrossRefGoogle ScholarPubMed
Vedam, SS, Keall, PJ, Kini, VR, and Mohan, R. Determining parameters for respiration-gated radiotherapy. Med Phys 2001; 28(10): 2139–46.CrossRefGoogle ScholarPubMed
Shirato, H, Shimizu, S, Kitamura, K, et al. Four-dimensional treatment planning and fluoroscopic real-time tumor tracking radiotherapy for moving tumor. Int J Radiat Oncol Biol Phys 2000; 48(2): 435–42.CrossRefGoogle ScholarPubMed
Mornex, F, Girard, N, Beziat, C, et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies–mature results of the French phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006; 66(4): 1152–8.CrossRefGoogle ScholarPubMed
Park, W, Lim, DH, Paik, SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61(4): 1143–50.CrossRefGoogle ScholarPubMed
Kim, TH, Kim, DY, Park, JW, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006; 29(6): 568–75.CrossRefGoogle ScholarPubMed
Liu, MT, Li, SH, Chu, TC, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 2004; 34(9): 532–9.CrossRefGoogle ScholarPubMed
Llovet, JM, Real, MI, Montana, X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359(9319): 1734–9.CrossRefGoogle ScholarPubMed
Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5): 1164–71.CrossRefGoogle ScholarPubMed
Seong, J, Park, HC, Han, KH, and Chon, CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003; 55(2): 329–36.CrossRefGoogle ScholarPubMed
Li, B, Yu, J, Wang, L, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma. Am J Clin Oncol 2003; 26(4): e92–9.CrossRefGoogle ScholarPubMed
Guo, WJ and Yu, EX. Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 2000; 73(874): 1091–7.CrossRefGoogle ScholarPubMed
Wu, DH, Liu, L, and Chen, LH. Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2004; 10(15): 2184–9.CrossRefGoogle ScholarPubMed
Zeng, ZC, Tang, ZY, Fan, J, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004; 10(5): 307–16.CrossRefGoogle ScholarPubMed
Ishikura, S, Ogino, T, Furuse, J, et al. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002; 25(2): 189–93.CrossRefGoogle ScholarPubMed
Yamada, K, Izaki, K, Sugimoto, K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003; 57(1): 113–19.CrossRefGoogle ScholarPubMed
Lin, CS, Jen, YM, Chiu, SY, et al. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36(4): 212–17.CrossRefGoogle ScholarPubMed
Kirilova, A, Lockwood, G, Choi, P, et al. Three-dimensional motion of liver tumors using cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2008; 71(4): 1189–95.CrossRefGoogle ScholarPubMed
Dvorak, P, Georg, D, Bogner, J, Kroupa, B, Dieckmann, K, and Potter, R. Impact of IMRT and leaf width on stereotactic body radiotherapy of liver and lung lesions. Int J Radiat Oncol Biol Phys 2005; 61(5): 1572–81.CrossRefGoogle ScholarPubMed
Cheng, JC, Wu, JK, Huang, CM, et al. Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy for patients with hepatocellular carcinoma and radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2003; 56(1): 229–34.CrossRefGoogle ScholarPubMed
Thomas, E, Chapet, O, Kessler, ML, Lawrence, TS, and Ten Haken, RK. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys 2005; 62(2): 571–8.CrossRefGoogle ScholarPubMed
Fuss, M, Salter, BJ, Herman, TS, and Thomas, CRExternal beam radiation therapy for hepatocellular carcinoma: Potential of intensity-modulated and image-guided radiation therapy. Gastroenterology 2004; 127(5 Suppl 1): S206–17.CrossRefGoogle ScholarPubMed
Blomgren, H, Lax, I, Naslund, I, and Svanström, R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Acta Oncol 1995; 34: 861–70.CrossRefGoogle ScholarPubMed
Herfarth, KK, Debus, J, Lohr, F, et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol 2001; 19: 164–70.CrossRefGoogle ScholarPubMed
Herfarth, KK, Debus, J, and Wannenmacher, M. Stereotactic radiation therapy of liver metastases: Update of the initial phase I/II trial. Front Radiat Ther Oncol 2004; 38: 100–5.CrossRefGoogle ScholarPubMed
Wulf, J, Guckenberger, M, and Haedinger, U. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol 2006; 45: 838–47.CrossRefGoogle ScholarPubMed
Mendez, Romero A, Wunderink, W, Hussain, SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 2006; 45(7): 831–7.CrossRefGoogle Scholar
Tse, RV, Hawkins, M, Lockwood, G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26(4): 657–64.CrossRefGoogle ScholarPubMed
Blomgren, H, Ingmar, L, Goranson, H, et al. Radiosurgery for tumors in the body: Clinical experience using a new method. J Radiosurg 1998; 1(1): 63–74.CrossRefGoogle Scholar
Hoyer, M, Roed, H, Hansen, AT, et al. Phase II study on stereotactic body radiotherapy for colorectal metastases. Acta Oncol 2006; 45: 823–30.CrossRefGoogle ScholarPubMed
Kavanagh, BD, Schefter, TE, Cardenes, HR, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 2006; 45: 848–55.CrossRefGoogle ScholarPubMed
Chiba, T, Tokuuye, K, Matsuzaki, Y, et al. Proton beam therapy for hepatocellular carcinoma: A retrospective review of 162 patients. Clin Cancer Res 2005; 11(10): 3799–805.CrossRefGoogle ScholarPubMed
Kawashima, M, Furuse, J, Nishio, T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005; 23(9): 1839–46.CrossRefGoogle ScholarPubMed
Hata, M, Tokuuye, K, Sugahara, S, et al. Proton beam therapy for hepatocellular carcinoma patients with severe cirrhosis. Strahlenther Onkol 2006; 182(12): 713–20.CrossRefGoogle ScholarPubMed
Bush, DA, Hillebrand, DJ, Slater, JM, and Slater, JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology 2004; 127(5 Suppl 1): S189–93.CrossRefGoogle ScholarPubMed
Kato, H, Tsujii, H, Miyamoto, T, et al. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 2004; 59(5): 1468–76.CrossRefGoogle ScholarPubMed
Goin, JE, Salem, R, Carr, BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: Factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16(2 Pt 1): 205–13.CrossRefGoogle ScholarPubMed
Salem, R, Lewandowski, RJ, Atassi, B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16(12): 1627–39.CrossRefGoogle Scholar
Lau, WY, Leung, WT, Ho, S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer 1994; 70(5): 994–9.CrossRefGoogle ScholarPubMed
Kulik, LM, Carr, BI, Mulcahy, MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47(1): 71–81.CrossRefGoogle ScholarPubMed
Kennedy, A, Nag, S, Salem, R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 2007; 68(1): 13–23.CrossRefGoogle ScholarPubMed
Llovet, J, Ricci, S, Mazzaferro, V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol (Meeting Abstracts) 2007; 25(18S): LBA1.Google Scholar
Tse, RV, Guha, C, and Dawson, . Conformal radiotherapy for hepatocellular carcinoma. Crit Rev Oncol Hematol 2008; 67(2): 113–23.CrossRefGoogle ScholarPubMed
Parkin, DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43.CrossRefGoogle ScholarPubMed
Donato, F, Boffetta, P, and Puoti, M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347–54.3.0.CO;2-2>CrossRefGoogle Scholar
El-Serag, HB and Rudolph, KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–76.CrossRefGoogle ScholarPubMed
Huang, CC, Wu, MC, Xu, GW, et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84: 262–4.CrossRefGoogle ScholarPubMed
Gish, RG, Porta, C, Lazar, L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069–75.CrossRefGoogle ScholarPubMed
Lai, CL, Wu, PC, Chan, GC, Lok, AS, and Lin, HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479–83.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Colleoni, M, Nole, F, Di Bartolomeo, M, Braud, F, and Bajetta, E. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology 1992; 49: 139–42.CrossRefGoogle ScholarPubMed
Dobbs, NA, Twelves, CJ, Rizzi, P, et al. Epirubicin in hepatocellular carcinoma: Pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994; 34: 405–10.CrossRefGoogle ScholarPubMed
Pohl, J, Zuna, I, Stremmel, W, and Rudi, J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001; 47: 359–65.CrossRefGoogle ScholarPubMed
Porta, C, Moroni, M, Nastasi, G, and Arcangeli, G. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: Preliminary results of a phase II study. Oncology 1995; 52: 487–91.CrossRefGoogle Scholar
Tetef, M, Doroshow, J, Akman, S, et al. 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: A phase II trial. Cancer Invest 1995; 13: 460–3.CrossRefGoogle ScholarPubMed
Fuchs, CS, Clark, JW, Ryan, DP, et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002; 94: 3186–91.CrossRefGoogle ScholarPubMed
Guan, Z, Wang, Y, Maoleekoonpairoj, S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer 2003; 89: 1865–9.CrossRefGoogle ScholarPubMed
Yang, TS, Lin, YC, Chen, JS, Wang, HM, and Wang, CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89: 750–6.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Okada, S, Okazaki, N, Nose, H, Shimada, Y, Yoshimori, M, and Aoki, K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 1993; 50: 22–6.CrossRefGoogle ScholarPubMed
Boige, V, Taieb, J, Hebbar, M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: A multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006; 42: 456–9.CrossRefGoogle ScholarPubMed
Wall, JG, Benedetti, JK, O'Rourke, MA, Natale, RB, and Macdonald, JS. Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study. Invest New Drugs 1997; 15: 257–60.CrossRefGoogle ScholarPubMed
Wierzbicki, R, Ezzat, A, Abdel-Warith, A, et al. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma (HCC). Ann Oncol 1994; 5: 466–7.CrossRefGoogle Scholar
Chao, Y, Chan, WK, Birkhofer, MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78: 34–9.CrossRefGoogle ScholarPubMed
Hebbar, M, Ernst, O, Cattan, S, et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology 2006; 70: 154–8.CrossRefGoogle ScholarPubMed
Lee, J, Park, JO, Kim, WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 2004; 54: 385–90.CrossRefGoogle ScholarPubMed
Yang, TS, Wang, CH, Hsieh, RK, Chen, JS, and Fung, MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: A phase I-II trial. Ann Oncol 2002; 13:1771–8.CrossRefGoogle ScholarPubMed
Bobbio-Pallavicini, E, Porta, C, Moroni, M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study. Eur J Cancer 1997; 33: 1784–8.CrossRefGoogle ScholarPubMed
Tanioka, H, Tsuji, A, Morita, S, et al. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891–7.Google ScholarPubMed
Parikh, PM, Fuloria, J, Babu, G, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol 2005; 26: 115–18.Google ScholarPubMed
Louafi, S, Boige, V, Ducreux, M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 2007; 109: 1384–90.CrossRefGoogle ScholarPubMed
Boige, V, Raoul, JL, Pignon, JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03–03 trial. Br J Cancer 2007; 97: 862–7.CrossRefGoogle ScholarPubMed
Boucher, E, Corbinais, S, Brissot, P, Boudjema, K, and Raoul, JL. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 2002; 50: 305–8.CrossRefGoogle Scholar
Ikeda, M, Okusaka, T, Ueno, H, Takezako, Y, and Morizane, C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005; 103: 756–62.CrossRefGoogle ScholarPubMed
Kim, SJ, Seo, HY, Choi, JG, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006; 57: 436–42.CrossRefGoogle ScholarPubMed
Park, SH, Lee, Y, Han, SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6: 3.CrossRefGoogle ScholarPubMed
Lai, CL, Lau, JY, Wu, PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993; 17: 389–94.CrossRefGoogle ScholarPubMed
A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group. Cancer 1990; 66: 135–9.
Yeo, W, Mok, TS, Zee, B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532–8.CrossRefGoogle ScholarPubMed
Wilhelm, SM, Carter, C, Tang, L, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099–109.CrossRefGoogle ScholarPubMed
Liu, L, Cao, Y, Chen, C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851–8.CrossRefGoogle ScholarPubMed
Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.CrossRefGoogle ScholarPubMed
Zhu, AX, Sahani, DV, di Tomaso, E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007; 25: Abstract 4637.Google Scholar
Thomas, MB, Chadha, R, Glover, K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059–67.CrossRefGoogle ScholarPubMed
Philip, PA, Mahoney, MR, Allmer, C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657–63.CrossRefGoogle ScholarPubMed
Zhu, AX, Stuart, K, Blaszkowsky, LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 581–9.CrossRefGoogle ScholarPubMed
Asnacios, A, Fartoux, L, Romano, O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study. Cancer 2008; 112(12): 2733–9.CrossRefGoogle ScholarPubMed
Schwartz, JD, Schwartz, M, Lehrer, D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006; 24: Abstract 4144.Google Scholar
Jain, RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987–9.CrossRefGoogle ScholarPubMed
Zhu, AX, Blaszkowsky, LS, Ryan, DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 1898–903.CrossRefGoogle ScholarPubMed
Thomas, MB, Chadha, R, Iwasaki, M, Glover, K, and Abbruzzese, JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25: Abstract 4567.Google Scholar
Cillo, U, Vitale, A, Grigoletto, F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723–31.CrossRefGoogle ScholarPubMed
Marrero, JA, Fontana, RJ, Barrat, A, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707–16.CrossRefGoogle Scholar
Bruix, J and Sherman, M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–36.CrossRefGoogle ScholarPubMed
Bruix, J, Sherman, M, Llovet, JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–30.CrossRefGoogle ScholarPubMed
Levy, I and Sherman, M. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881–5.CrossRefGoogle Scholar
Farinati, F, Rinaldi, M, Gianni, S, and Naccarato, R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000; 89: 2266–73.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Ueno, S, Tanabe, G, Sako, K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529–34.CrossRefGoogle ScholarPubMed
Helton, W and Strasberg, S. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: Rationale and overview of the conference. HPB (Oxford) 2003; 5: 238–42.CrossRefGoogle ScholarPubMed
Llovet, JM, Di Bisceglie, AM, Bruix, J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698–711.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×